MA31162B1 - Préparation pharmaceutique pour soulager l'endométriose - Google Patents
Préparation pharmaceutique pour soulager l'endométrioseInfo
- Publication number
- MA31162B1 MA31162B1 MA32138A MA32138A MA31162B1 MA 31162 B1 MA31162 B1 MA 31162B1 MA 32138 A MA32138 A MA 32138A MA 32138 A MA32138 A MA 32138A MA 31162 B1 MA31162 B1 MA 31162B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- bone density
- dilution
- endometriosis
- uterine lining
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000010790 dilution Methods 0.000 title 1
- 239000012895 dilution Substances 0.000 title 1
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 230000037182 bone density Effects 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229960001616 chlormadinone acetate Drugs 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000546 inhibition of ovulation Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition pharmaceutique conçue pour traiter une endométriose sans réduire la densité osseuse. Cette composition contient un gestagène anti-androgène, de préférence 17a-cyanométhyl-17-ß-hydroxyestra-4,9-dièn-3one (dienogest), acétate de cyprotérone ou acétate de chlormadinone, dans une dose journalière qui est au maximum deux fois supérieure à la dose d'inhibition d'ovulation, avec un ou plusieurs adjuvants/supports pharmaceutiquement acceptables. La composition pharmaceutique selon cette invention permet de traiter une endométriose sans influencer négativement le métabolisme osseux, ni la densité osseuse, et permet en même temps de maintenir à un niveau acceptable les effets secondaires connus (par ex. Bouffées de chaleur, acné, influence négative sur le profil lipidique) engendrés par les médicaments classiques. Ladite composition pharmaceutique est par conséquent adaptée à une application à long terme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07004202A EP1977752A1 (fr) | 2007-03-01 | 2007-03-01 | Composition pharmaceutique destinée à réduire l'endométriose |
| PCT/EP2008/001451 WO2008104342A1 (fr) | 2007-03-01 | 2008-02-23 | Préparation pharmaceutique conçue pour traiter une endométriose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31162B1 true MA31162B1 (fr) | 2010-02-01 |
Family
ID=38045772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32138A MA31162B1 (fr) | 2007-03-01 | 2009-08-04 | Préparation pharmaceutique pour soulager l'endométriose |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1977752A1 (fr) |
| JP (1) | JP2010520159A (fr) |
| KR (1) | KR20090119829A (fr) |
| CN (1) | CN101583364A (fr) |
| AU (1) | AU2008221012A1 (fr) |
| BR (1) | BRPI0806598A2 (fr) |
| CA (1) | CA2673936A1 (fr) |
| CO (1) | CO6190606A2 (fr) |
| CR (1) | CR10912A (fr) |
| DO (1) | DOP2009000171A (fr) |
| EA (1) | EA200900829A1 (fr) |
| EC (1) | ECSP099482A (fr) |
| MA (1) | MA31162B1 (fr) |
| MX (1) | MX2009007259A (fr) |
| NZ (1) | NZ577761A (fr) |
| SV (1) | SV2009003324A (fr) |
| TN (1) | TN2009000263A1 (fr) |
| WO (1) | WO2008104342A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
| CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
| CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
| TW202523334A (zh) * | 2023-12-13 | 2025-06-16 | 大陸商長春金賽藥業有限責任公司 | 原位皮下植入的女性激素調節組合物及其製備方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| EP1535618A1 (fr) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| EP1655031A1 (fr) * | 2004-10-08 | 2006-05-10 | Schering AG | Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/fr not_active Withdrawn
-
2008
- 2008-02-23 EP EP08707797A patent/EP2059248A1/fr not_active Ceased
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 CA CA002673936A patent/CA2673936A1/fr not_active Abandoned
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/fr not_active Ceased
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Withdrawn
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SV2009003324A (es) | 2009-10-02 |
| CR10912A (es) | 2009-08-13 |
| CA2673936A1 (fr) | 2008-09-04 |
| TN2009000263A1 (en) | 2010-10-18 |
| EA200900829A1 (ru) | 2010-02-26 |
| CN101583364A (zh) | 2009-11-18 |
| CO6190606A2 (es) | 2010-08-19 |
| DOP2009000171A (es) | 2009-08-31 |
| EP1977752A1 (fr) | 2008-10-08 |
| BRPI0806598A2 (pt) | 2014-05-06 |
| WO2008104342A1 (fr) | 2008-09-04 |
| KR20090119829A (ko) | 2009-11-20 |
| MX2009007259A (es) | 2009-07-10 |
| AU2008221012A1 (en) | 2008-09-04 |
| NZ577761A (en) | 2012-03-30 |
| EP2059248A1 (fr) | 2009-05-20 |
| JP2010520159A (ja) | 2010-06-10 |
| ECSP099482A (es) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Narang et al. | Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier | |
| Kim et al. | Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function | |
| Selzner et al. | Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism | |
| BladÉ et al. | Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | |
| Filliol et al. | RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis | |
| Lleo et al. | Hepatotoxicity of immune check point inhibitors: Approach and management | |
| Ikeuchi et al. | Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report | |
| MA31162B1 (fr) | Préparation pharmaceutique pour soulager l'endométriose | |
| EP3530288A3 (fr) | Procédés pour le traitement d'états pathologiques liés à l'activation du complément masp-2 dépendant | |
| EP3276004A3 (fr) | Procédés de traitement d'une maladie rénale chronique | |
| Kim et al. | Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma | |
| Loughlin | Calcium channel blockers and prostate cancer | |
| Zhang et al. | A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen | |
| Rini et al. | Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma | |
| van Golen et al. | The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters | |
| Gomez-Lechon et al. | The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes | |
| Li et al. | Oleanolic acid inhibits proliferation and induces apoptosis in NB4 cells by targeting PML/RARα | |
| Jensen et al. | Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia | |
| Harbaum et al. | Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity | |
| Root et al. | Burkitt’s lymphoma of the testicle: report of 2 cases occurring in elderly patients | |
| Butty et al. | Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine | |
| Mathurin et al. | Treatment of severe forms of alcoholic hepatitis: where are we going? | |
| Mele et al. | Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia | |
| Lamarre et al. | A quantitative study to assess synergistic interactions between urotensin II and angiotensin II | |
| Pocha et al. | Immune-mediated colitis: Important to recognize and treat |